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Since the first days of angioplasty, restenosis has been the
major limitation. Over the brief history of percutaneous
interventions, therapies to prevent restenosis have come and
gone with a frequency that rivals treatments for rheumatoid
arthritis over the last hundred years. We have also learned to
be skeptical regarding any claim of benefit from a therapy
for established restenosis. In the recently published Amer-
ican Heart Association and the American College of Car-
diology Guidelines on Percutaneous Coronary Interventions
(1), there are no recommendations for any therapy for
restenotic lesions that are not stented.
However, since stenting has become the predominant
percutaneous coronary artery intervention, the most com-
mon form of restenosis is currently in-stent restenosis.
There is now an approved treatment for this condition—
endovascular brachytherapy. Three randomized trials, two
using beta radiation (START, INHIBIT) and one using
gamma radiation (GAMMA-1), have shown significant
reduction in re-restenosis of treated in-stent lesions that
receive radiation therapy. Before brachytherapy can be
delivered, mechanical removal or displacement of the ob-
structing lesion must be done. Also pertinent is the fact that
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only a minority of patients with in-stent restenosis are
currently being treated in centers in which brachytherapy is
available. Therefore, identification of lesion removal or
displacement methods that show an advantage would be
beneficial with and without radiation. In a large series of
in-stent restenosis lesions treated with balloon angioplasty,
rotary ablation, laser therapy or restenting, no method was
found to be superior and all lead to approximately the same
re-restenosis rates (2). Although the cutting balloon was
developed more than 10 years ago, it has only recently
become available in the U.S. Among other uses, it has been
suggested for in-stent restenosis.
Most claims for decreasing restenosis have been made on
clinical and angiographic grounds without exploration of
the mechanisms whereby these therapies may be effective.
The current report from Adamian et al. (3) is no exception
to this generalization. Nevertheless, a great deal of what is
done in interventional cardiology is based on results ob-
tained by experienced and trusted colleagues who try new
devices in the early stage of their development.
The current observations reported by Adamian et al. (3)
in this issue of the Journal involve four selected therapies for
in-stent restenosis: balloon angioplasty, rotational ablation,
stent placement and cutting balloon angioplasty. These
therapies were not randomized, and the authors state that
selection was based on operator preference without major
consideration for baseline differences. It is also pointed out
that the cutting balloon became popular during the latter
part of the experience reported herein and, therefore, there
was temporal inhomogeneity of the therapies delivered. In
addition, the authors sought to reduce clinical and angio-
graphic variables by a matching process that reduced the
total number of in-stent restenosis cases from 648 to 258
following the matching. Four relatively equal-sized groups
were created without major defined differences in baseline
demographic characteristics. Angiographic follow-up was
planned around the six-month mark and clinical follow-up
averaged 11 months. The authors found no difference in the
restenosis rate or the target vessel revascularization for
balloon angioplasty, restenting or rotary ablation therapies
but found a significant improvement in the restenosis rate
among those lesions treated with the cutting balloon.
Concerning these results, there are reasons to be skeptical
and there are reasons to be hopeful.
The authors point out the obvious limitations of a small,
nonrandomized registry; however, causes for these results
other than chance occurrence should be explored. Although
not mentioned in this communication, totally occluded
stents have been reported to have the highest re-restenosis
risk. The numbers are small, and it is not emphasized but
the baseline presence of a totally occluded stent was 10.8%
and 8.9% in the percutaneous transluminal coronary angio-
plasty (PTCA) and stent groups, respectively, whereas it
was only 1.8% in the cutting balloon group. In addition, if
a bias in favor of the effectiveness of the cutting balloon
occurred during the process of this study, then the enthu-
siasm for reintervention in the cutting balloon group may
have been less than for other therapies. This potential
“placebo effect” can even influence randomized trials but one
would assume that the angiographic assessment of the lesion
severity at follow-up would not be influenced by the prior
therapy given. The results of this series are better than some
other observations of cutting balloon angioplasty. This may
have resulted from a different method of applying the
technology. In some prior observations, cutting balloon was
utilized with low inflation pressures which could have
produced less vessel expansion. This was not the case in the
present study where the average maximum inflation pressure
was 10.7 barr compared to 13.1 barr in the PTCA group.
Also, the balloon to vessel ratio was the same for all groups
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at 1:1.2. Finally, the overall in-stent restenosis rate during
the time frame of this study (1997 to 1999) was 38%. Given
the earlier reports from the same group, many will find this
surprising. The authors have pointed out that the potential
reason for this finding is the changing character of the
lesions treated. Stented lesions have indeed become longer
and vessel diameters have become smaller. The character-
istics of in-stent restenosis lesions also may have changed
leading to an overall high re-restenosis rate with most of the
therapies tried. Stent underdeployment has been empha-
sized by many, including this group, as a cause of failure
when treating in-stent restenosis. However, since there is no
intravascular ultrasound control in this study, the influence
of completeness of stent deployment on the outcomes must
remain speculative.
Despite these concerns, there are clear reasons to be
hopeful for this technology. One of the major concerns
about treating diffuse in-stent restenosis with balloon an-
gioplasty is the appearance of the segment after treatment.
Since avoiding additional stenting is now often a priority,
methods of assuring an adequate post-treatment lumen are
desirable. Improvement in postprocedure minimal lumen
diameter (MLD) was very little and not significant; how-
ever, the late loss advantage for the cutting balloon in this
series is quite striking. Late loss of 0.63 mm occurred in the
cutting balloon group, whereas late loss was well over 1 mm
for the other groups. Since the final MLD after the
procedure was similar for the three nonstented groups, this
reduced late loss was the important difference in the study.
Are there mechanistic explanations for the finding of a
reduced amount of proliferative tissue in the cutting balloon
group? The authors speculate that the mechanism for lumen
enlargement with the cutting balloon is plaque extrusion
through the stent struts. However, this is also the likely
explanation for lumen enlargement with balloon angioplasty
as well as rotary ablation and restenting procedures. If
disrupting the restenotic tissue prior to extruding it through
the stent struts is helpful, one would expect rotary ablation
to be effective. The rotablator not only disrupts the tissue,
but also removes some of it so that less is available for
extrusion through the struts. However, the ARTIST Trial
comparing direct rotary ablation with balloon angioplasty
for in-stent restenosis failed to show superiority for the
ablative approach (4). It remains attractive, however, to
speculate as to whether reduction in the amount of prolif-
erative tissue extruded into the vessel wall outside the stent
could result in a decreased stimulus for cytokine release and
subsequent proliferation and migration. Since in-stent rest-
enotic lesions have been found to be composed in large
measure by proteoglycans and are frequently fairly echolu-
cent, they have a high water content. Could the process of
incising these lesions and then squeezing them result in
desiccating the material with loss of liquid components into
the vessel lumen? If this occurs, then less volume of
neointimal tissue would be available for trans-stent extru-
sion.
The preceding is pure speculation, but this hypothesis
should be tested in experimental studies. Regardless of the
cause of the benfit shown by Adamian et al. (3) the standard
recommendation is that there should now be a well-
controlled clinical trial of the cutting balloon versus plain
old balloon angioplasty. A modest-sized randomized trial
comparing balloon angioplasty to cutting balloon therapy
for in-stent restenotic lesions is nearing completion in
Europe. This trial, led by Dr. Colombo, will be of great
interest as it should remove undetected baseline differences
that could have influenced this observational study. How-
ever, the problem is that since endovascular brachytherapy
has demonstrated efficacy for in-stent restenosis, that ther-
apy is increasingly applied. Controlled trials of brachyther-
apy comparing balloon angioplasty to cutting balloon would
be a logical next step. As the authors point out, the cutting
balloon may be helpful for its tendency not to slip during
inflation in in-stent restenotic lesions regardless of its effect
on restenosis rates. This may be of particular advantage for
patients undergoing brachytherapy since it would avoid
injury to the distal or proximal artery which is an important
component of the “edge effect” restenotic lesions sometimes
seen with brachytherapy. On the down side, it is less
maneuverable and is limited in length.
The current observation raises many questions. Whether
this technology remains one that is favored for in-stent
restenosis by certain enthusiasts or becomes a documented
superior approach depends on the willingness to mount
definitive randomized trials.
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